Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A R Crossman

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Brain Research|July 10, 1992
Lipocortin-1 inhibits NMDA receptor-mediated neuronal damage in the striatum of the ratM D Black, F Carey, A R Crossman, et al.
Experimental Neurology|May 1, 1996
Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's diseaseY P Maneuf, S Duty, C J Hille, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|July 1, 1988
Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridineC E Clarke, S Boyce, M A Sambrook, et al.
Brain Research|October 29, 1990
The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiographyR G Robertson, C A Clarke, S Boyce, et al.
Brain Research|June 12, 1995
Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's diseaseY P Maneuf, I J Mitchell, A R Crossman, et al.
Experimental Neurology|October 30, 2001
Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's diseaseC J Hille, S H Fox, Y P Maneuf, et al.
Neuroscience Letters|September 30, 1991
Reduction of [125I]Bolton Hunter CCK8 and [3H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkeyW C Graham, D R Hill, G N Woodruff, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 2, 2001
Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxanS H Fox, B Henry, M P Hill, et al.
Experimental Neurology|July 13, 2004
The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's diseaseJ E Nash, P Ravenscroft, S McGuire, et al.
Neurology|December 12, 2001
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot studyK A Sieradzan, S H Fox, M Hill, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Brain Research|July 10, 1992
Lipocortin-1 inhibits NMDA receptor-mediated neuronal damage in the striatum of the ratM D Black, F Carey, A R Crossman, et al.
Experimental Neurology|May 1, 1996
Modulation of GABA transmission by diazoxide and cromakalim in the globus pallidus: implications for the treatment of Parkinson's diseaseY P Maneuf, S Duty, C J Hille, et al.
Naunyn-Schmiedeberg'S Archives of Pharmacology|July 1, 1988
Behavioural effects of (+)-4-propyl-9-hydroxynaphthoxazine in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridineC E Clarke, S Boyce, M A Sambrook, et al.
Brain Research|October 29, 1990
The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiographyR G Robertson, C A Clarke, S Boyce, et al.
Brain Research|June 12, 1995
Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's diseaseY P Maneuf, I J Mitchell, A R Crossman, et al.
Experimental Neurology|October 30, 2001
Antiparkinsonian action of a delta opioid agonist in rodent and primate models of Parkinson's diseaseC J Hille, S H Fox, Y P Maneuf, et al.
Neuroscience Letters|September 30, 1991
Reduction of [125I]Bolton Hunter CCK8 and [3H]MK-329 (devazepide) binding to CCK receptors in the substantia nigra/VTA complex and its forebrain projection areas following MPTP-induced hemi-parkinsonism in the monkeyW C Graham, D R Hill, G N Woodruff, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 2, 2001
Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxanS H Fox, B Henry, M P Hill, et al.
Experimental Neurology|July 13, 2004
The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's diseaseJ E Nash, P Ravenscroft, S McGuire, et al.
Neurology|December 12, 2001
Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot studyK A Sieradzan, S H Fox, M Hill, et al.
Pageof 10